



Experts Report From Major International Neuromuscular Meeting on DMD and LGMD Highlights

FOR MORE INFORMATION: Visit <http://www.MuscularDystrophyCME.com>

- Release Date: 12/3/20
- Expiration Date: 12/2/21
- Short videos with links to abstracts and relevant data

This education is targeted to neurologists, neuromuscular specialists, pediatricians, nurses, and other health care providers who manage patients with Duchenne's muscular dystrophy and Limb-Girdle muscular dystrophy.

Why complete this education?

- There are **new therapies**, including gene therapy, in clinical trials for DMD and LGMD
- Experts in DMD and LGMD share how new information presented at an international meeting changes **patient management**
- The neuromuscular specialist or neurologist is the coordinator for **multidisciplinary management** of these patients
- **FREE CME!**

Faculty

Jerry Mendell, MD
Center for Gene Therapy
Nationwide Children's Hospital

Eugenio Mercuri, MD, PhD
Professor of Pediatric Neurology
Catholic University of the Sacred Heart

Brenda Wong, MD
Director, DMD Center
UMass Memorial Medical Center

Video titles include:

Excitement in New Therapeutics for DMD
Novel Approaches to Gene Therapy for LGMD
Consistent Data for RNA-based Therapies Treating DMD
Multidisciplinary Approach to Standards of Care for Patients with DMD
Is Personalized Gene Therapy On the Horizon for Muscular Dystrophy?

EDUCATIONAL LEARNING OBJECTIVES

- Review new clinical information on the management of patients with DMD and LGMD presented at major congresses
- Discuss the implication of this information on current clinical practices for clinicians

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians

The France Foundation designates this enduring activity for a maximum of 0.5 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Sarepta Therapeutics, Inc